$312.07
-2.08-0.66%
Last update: Nov 10, 10:52 AM
Ligand Pharmaceuticals Inc
LGNDNASDAQ
Ligand Pharmaceuticals rose 50.1% from $209.29 to $314.15, ahead of the S&P 500's +10.5%. Its worst day was May 7 (−9.6%), and its low came Feb 12 at $181.65.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Ligand Pharmaceuticals shares fell 8.7%, while the S&P 500 fell 0.2%.
−8.7% · S&P 500 −0.2%
Ligand Pharmaceuticals closed at its lowest level of the year, 13.2% below where the year started.
−2.3% · S&P 500 −1.5%
Story events cover the past 12 months · Times ET
EPS of $2.02 beat the $1.15 estimate on $59.7M revenue (est. $56.6M); FY revenue guidance of $245.0M–$285.0M against the $266.0M consensus.
+2.5% · S&P 500 −0.6%
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc.
+8.9%, the year's best day · S&P 500 +1.2%
EPS of $1.63 missed the $1.64 estimate on $51.7M revenue (est. $59.1M); FY revenue guidance of $270.0M–$310.0M against the $293.1M consensus.
−9.6%, the year's worst day · S&P 500 −0.3%
Ligand Pharmaceuticals shares rose 6.6%, while the S&P 500 fell 1.5%.
+6.6%, on 2M shares, the year's heaviest volume · S&P 500 −1.5%
EPS of $2.37 beat the $1.84 estimate on $63.7M revenue (est. $63.5M); FY revenue guidance of $270.0M–$310.0M against the $287.5M consensus.
−0.8% · S&P 500 −0.2%
EPS of $2.67 beat the $2.15 estimate on $78.7M revenue (est. $77.2M); FY revenue guidance of $225.0M–$250.0M against the $289.1M consensus.
−0.5% · S&P 500 −0.4%
Where it ended: a close of $314.15 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $2.71, revenue est. $96.8M).
Nothing in the past 12 months.
All LGND dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LGND and SPY from Benzinga historical bars. Not investment advice.
